Clinical Trials Browser

Phase 2 × Unknown × osimertinib × Clear all

NCT03865511 2024-02-28

MELROSE

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04974879 2023-03-29

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Phase 2 Unknown

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02504346 2023-03-28

TREM

Phase 2 Unknown

Lung Neoplasms

NCT04811001 2023-02-21

CAPLAND

Phase 2 Unknown

NSCLC

NCT05507606 2022-08-19

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05458726 2022-07-26

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05085054 2022-05-20

Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05132777 2021-11-24

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02824952 2021-11-18

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02736513 2021-09-02

Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases

Phase 2 Unknown

Brain Neoplasms, Lung Neoplasms

NCT03257124 2021-08-16

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Phase 2 Unknown

Non-Small Cell Lung Cancer With EGFR T790M Mutation

NCT04988607 2021-08-03

Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC

Phase 2 Unknown

Lung Neoplasms

NCT04829019 2021-04-02

Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI

Phase 2 Unknown

Neurocognitive

NCT04425681 2020-06-11

OWBLM

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04148898 2019-11-04

OWONBNSCLCLM

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04029350 2019-08-21

ALTN-03

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02771314 2019-02-22

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02811354 2018-09-20

PLASMA

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03460275 2018-03-09

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03424759 2018-02-07

Uncommon EGFR AZD9291

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung